Bank of America Corp DE Sells 28,855 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of America Corp DE cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 75,799 shares of the company's stock after selling 28,855 shares during the quarter. Bank of America Corp DE owned approximately 0.26% of Krystal Biotech worth $11,875,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in KRYS. Covestor Ltd grew its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after buying an additional 642 shares during the last quarter. KBC Group NV lifted its position in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after acquiring an additional 297 shares during the period. Blue Trust Inc. grew its stake in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares during the last quarter. US Bancorp DE grew its stake in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the last quarter. Finally, Certuity LLC acquired a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $214,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KRYS shares. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Citigroup lowered their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. Finally, Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $211.13.

Krystal Biotech Trading Up 0.1%

Krystal Biotech stock traded up $0.07 during midday trading on Wednesday, hitting $126.52. The stock had a trading volume of 22,751 shares, compared to its average volume of 307,807. The business has a fifty day moving average price of $158.82 and a 200 day moving average price of $166.00. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The stock has a market cap of $3.66 billion, a P/E ratio of 42.42 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).